| Description | RAGE antagonist peptide acetate is an advanced antagonist of glycation end products (RAGE). RAGE antagonist peptide acetate possesses anti-tumor and anti-inflammatory activities. RAGE antagonist peptide acetate prevents RAGE from binding with several of its most important ligands, including HMGB-1, S100P, and S100A4. |
| In vitro | 在癌细胞中，RAGE antagonist peptide acetate 降低了配体刺激RAGE激活NFκB[2]的能力。 |
| In vivo | 在携带哮喘的小鼠中，RAGE antagonist peptide acetate（RAP; 4 mg/kg; i.p.）减弱了气道反应性、气道炎症和杯状细胞化生，并降低了Th2细胞因子的释放。RAGE antagonist peptide acetate还降低了β-连环蛋白的总水平、细胞质和核水平，增强了Ser33/37/Thr41处的β-连环蛋白磷酸化，引发了泛素化，下调了β-连环蛋白靶基因的表达，并倾向于将β-连环蛋白保持在细胞膜上，将β-连环蛋白从一个信号激活模式转变为一个粘附功能。RAGE antagonist peptide acetate减缓了胰腺肿瘤的生长和转移，也抑制了胶质瘤肿瘤的生长。RAGE antagonist peptide acetate（100 μg）在体内抑制了PDAC细胞中RAGE介导的基础NFκB活性。 |
| molecular weight | 1332.61 |
| Molecular formula | C59H105N13O19S |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Lihong Yao, et al. The receptor for advanced glycation end products is required for β-catenin stabilization in a chemical-induced asthma model. Br J Pharmacol. 2016 Sep;173(17):2600-13. 2. Thiruvengadam Arumugam, et al. S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis. Clin Cancer Res. 2012 Aug 15;18(16):4356-64. |